The adverse effects of pramipexole on probability discounting are not reversed by acute D2 or D3 receptor antagonism
Orrù M, Strathman H, Floris G, Scheggi S, Levant B, Bortolato M. The adverse effects of pramipexole on probability discounting are not reversed by acute D2 or D3 receptor antagonism. European Neuropsychopharmacology 2020, 32: 104-119. PMID: 31983530, PMCID: PMC9325630, DOI: 10.1016/j.euroneuro.2020.01.005.Peer-Reviewed Original ResearchConceptsEffect of pramipexoleProbability discountingDopamine D<sub>2</sub>Monoamine-depleting agent reserpineD3 receptor antagonismAntagonist L-741,626Impulse-control disordersDopamine receptor agonistsRES-treated ratsSB-277011AAntagonist racloprideCombination of pramipexoleNucleus accumbensL-741,626Behavioral effectsNeurobehavioral mechanismsDopamine receptorsAntagonist GRAcute treatmentPramipexoleReceptor antagonismReceptor agonistsRisk takingDopamineImpulse
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply